GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Results] 38 weeks, 6kg, and satiety was the hard part — 61 comments in the full submission. View in context.
702
c/cagrilintide·submitted 1 year ago by u/noor_vermeulen

[Results] 38 weeks, 6kg, and satiety was the hard part

Labbranch of 9 comments

38 weeks, 6kg, and satiety was the hard part. Posting the boring middle of the process, because the internet is full of the start and the end and nothing else. Pulling the figures out of the title: 38 weeks and 6kg. All of it is written down as it happened rather than reconstructed. The tolerability tables were more…

Read the full submission and all 61 comments →

This branch

9 comments, started 1 year ago
u/emil_agyeman137 points·1 year ago

Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.

replysharereportpermalink
u/lucia_bruun81 points·1 year ago

Which trial and which readout?

replysharereportpermalink
u/pavel_halvorsen18 points·1 year ago

Asked a question here that turned out to be based on a mechanism confusion. Three people untangled it patiently.

replysharereportpermalink
u/noor_vermeulenOP10 points·1 year ago·edited

Monotherapy arm or combination arm?

replysharereportpermalink
u/lipid_panel_larrybloodwork3 points·1 year ago

Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.

replysharereportpermalink
u/titration_marshalmod · c/semaglutide21 points·1 year ago

Cosigning on the thin independent data. Fewer members test this, so the bands are wider and should be treated that way.

replysharereportpermalink
[deleted]8 points·1 year ago

[deleted]

replysharereportpermalink
u/noor_vermeulenOP3 points·1 year ago

Correcting myself upthread: I gave the 94-week figure and the paper reports 45 weeks.

replysharereportpermalink
u/viktor_nkemelu11 points·1 year ago

satiety signalling rather than incretin signalling

replysharereportpermalink

← back to the whole thread

About c/cagrilintide

Amylin analog pharmacology and the CagriSema combination: why amylin and GLP-1 co-agonism produces a different satiety profile, the REDEFINE readouts, and the very limited pool of people handling cagrilintide as research material.

19kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.com
Sponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
c/cagrilintide rules
  1. Amylin is not a GLP-1. Posts conflating them get corrected.
  2. CagriSema ratios in trials are fixed-dose. Do not extrapolate to self-mixing.
  3. Not approved anywhere. Keep posts descriptive, not instructional.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.